The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect.
 
Qiming Wang
No Relationships to Disclose
 
Baohui Han
No Relationships to Disclose
 
Kai Li
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose
 
Jianhua Shi
No Relationships to Disclose
 
Zhehai Wang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Jianxing He
No Relationships to Disclose
 
Yuankai Shi
No Relationships to Disclose
 
Weiqiang Chen
No Relationships to Disclose
 
Xiuwen Wang
No Relationships to Disclose
 
Yi Luo
No Relationships to Disclose
 
Kejun Nan
No Relationships to Disclose
 
Faguang Jin
No Relationships to Disclose
 
Baolan Li
No Relationships to Disclose